Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225828131> ?p ?o ?g. }
- W4225828131 endingPage "321" @default.
- W4225828131 startingPage "311" @default.
- W4225828131 abstract "BackgroundThere is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection.MethodsIn this cohort study, we used the national databases of the US Department of Veterans Affairs to build a cohort of 181 280 participants who had a positive COVID-19 test between March 1, 2020, and Sept 30, 2021, and survived the first 30 days of COVID-19; a contemporary control (n=4 118 441) that enrolled participants between March 1, 2020, and Sept 30, 2021; and a historical control (n=4 286 911) that enrolled participants between March 1, 2018, and Sept 30, 2019. Both control groups had no evidence of SARS-CoV-2 infection. Participants in all three comparison groups were free of diabetes before cohort entry and were followed up for a median of 352 days (IQR 245–406). We used inverse probability weighted survival analyses, including predefined and algorithmically selected high dimensional variables, to estimate post-acute COVID-19 risks of incident diabetes, antihyperglycaemic use, and a composite of the two outcomes. We reported two measures of risk: hazard ratio (HR) and burden per 1000 people at 12 months.FindingsIn the post-acute phase of the disease, compared with the contemporary control group, people with COVID-19 exhibited an increased risk (HR 1·40, 95% CI 1·36–1·44) and excess burden (13·46, 95% CI 12·11–14·84, per 1000 people at 12 months) of incident diabetes; and an increased risk (1·85, 1·78–1·92) and excess burden (12·35, 11·36–13·38) of incident antihyperglycaemic use. Additionally, analyses to estimate the risk of a composite endpoint of incident diabetes or antihyperglycaemic use yielded a HR of 1·46 (95% CI 1·43–1·50) and an excess burden of 18·03 (95% CI 16·59–19·51) per 1000 people at 12 months. Risks and burdens of post-acute outcomes increased in a graded fashion according to the severity of the acute phase of COVID-19 (whether patients were non-hospitalised, hospitalised, or admitted to intensive care). All the results were consistent in analyses using the historical control as the reference category.InterpretationIn the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes.FundingUS Department of Veterans Affairs and the American Society of Nephrology." @default.
- W4225828131 created "2022-05-05" @default.
- W4225828131 creator A5044152940 @default.
- W4225828131 creator A5047490642 @default.
- W4225828131 date "2022-05-01" @default.
- W4225828131 modified "2023-10-18" @default.
- W4225828131 title "Risks and burdens of incident diabetes in long COVID: a cohort study" @default.
- W4225828131 cites W1967862917 @default.
- W4225828131 cites W1981343287 @default.
- W4225828131 cites W2009428399 @default.
- W4225828131 cites W2036193982 @default.
- W4225828131 cites W2092690624 @default.
- W4225828131 cites W2096391232 @default.
- W4225828131 cites W2514730604 @default.
- W4225828131 cites W2601152064 @default.
- W4225828131 cites W2773395370 @default.
- W4225828131 cites W2810551427 @default.
- W4225828131 cites W2907932858 @default.
- W4225828131 cites W2946854190 @default.
- W4225828131 cites W2989668089 @default.
- W4225828131 cites W2990638839 @default.
- W4225828131 cites W2999856875 @default.
- W4225828131 cites W3011134208 @default.
- W4225828131 cites W3023814660 @default.
- W4225828131 cites W3035586023 @default.
- W4225828131 cites W3036500399 @default.
- W4225828131 cites W3084212777 @default.
- W4225828131 cites W3087450863 @default.
- W4225828131 cites W3104627571 @default.
- W4225828131 cites W3106995227 @default.
- W4225828131 cites W3108395115 @default.
- W4225828131 cites W3111905760 @default.
- W4225828131 cites W3120214978 @default.
- W4225828131 cites W3120562100 @default.
- W4225828131 cites W3127484940 @default.
- W4225828131 cites W3149633446 @default.
- W4225828131 cites W3153493739 @default.
- W4225828131 cites W3155987937 @default.
- W4225828131 cites W3163131652 @default.
- W4225828131 cites W3163706616 @default.
- W4225828131 cites W3163839889 @default.
- W4225828131 cites W3165079828 @default.
- W4225828131 cites W3177081741 @default.
- W4225828131 cites W3194103068 @default.
- W4225828131 cites W3202042764 @default.
- W4225828131 cites W3203443071 @default.
- W4225828131 cites W3212377033 @default.
- W4225828131 cites W4205682741 @default.
- W4225828131 cites W4210511145 @default.
- W4225828131 cites W4211103437 @default.
- W4225828131 cites W4213310799 @default.
- W4225828131 cites W4225667321 @default.
- W4225828131 cites W4288040329 @default.
- W4225828131 doi "https://doi.org/10.1016/s2213-8587(22)00044-4" @default.
- W4225828131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35325624" @default.
- W4225828131 hasPublicationYear "2022" @default.
- W4225828131 type Work @default.
- W4225828131 citedByCount "227" @default.
- W4225828131 countsByYear W42258281312022 @default.
- W4225828131 countsByYear W42258281312023 @default.
- W4225828131 crossrefType "journal-article" @default.
- W4225828131 hasAuthorship W4225828131A5044152940 @default.
- W4225828131 hasAuthorship W4225828131A5047490642 @default.
- W4225828131 hasBestOaLocation W42258281312 @default.
- W4225828131 hasConcept C126322002 @default.
- W4225828131 hasConcept C134018914 @default.
- W4225828131 hasConcept C194828623 @default.
- W4225828131 hasConcept C201903717 @default.
- W4225828131 hasConcept C207103383 @default.
- W4225828131 hasConcept C2775969662 @default.
- W4225828131 hasConcept C2777180221 @default.
- W4225828131 hasConcept C2779134260 @default.
- W4225828131 hasConcept C3008058167 @default.
- W4225828131 hasConcept C44249647 @default.
- W4225828131 hasConcept C524204448 @default.
- W4225828131 hasConcept C555293320 @default.
- W4225828131 hasConcept C71924100 @default.
- W4225828131 hasConcept C72563966 @default.
- W4225828131 hasConceptScore W4225828131C126322002 @default.
- W4225828131 hasConceptScore W4225828131C134018914 @default.
- W4225828131 hasConceptScore W4225828131C194828623 @default.
- W4225828131 hasConceptScore W4225828131C201903717 @default.
- W4225828131 hasConceptScore W4225828131C207103383 @default.
- W4225828131 hasConceptScore W4225828131C2775969662 @default.
- W4225828131 hasConceptScore W4225828131C2777180221 @default.
- W4225828131 hasConceptScore W4225828131C2779134260 @default.
- W4225828131 hasConceptScore W4225828131C3008058167 @default.
- W4225828131 hasConceptScore W4225828131C44249647 @default.
- W4225828131 hasConceptScore W4225828131C524204448 @default.
- W4225828131 hasConceptScore W4225828131C555293320 @default.
- W4225828131 hasConceptScore W4225828131C71924100 @default.
- W4225828131 hasConceptScore W4225828131C72563966 @default.
- W4225828131 hasIssue "5" @default.
- W4225828131 hasLocation W42258281311 @default.
- W4225828131 hasLocation W42258281312 @default.
- W4225828131 hasLocation W42258281313 @default.
- W4225828131 hasOpenAccess W4225828131 @default.
- W4225828131 hasPrimaryLocation W42258281311 @default.